Search - tctmd.com

Displaying 361 - 380 of 1423

Sort: Relevancy | Date

Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering

News Conference News AHA 2022

Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering

November 08, 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

News Conference News AHA 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

Michael O'Riordan

November 07, 2022

Botulinum Toxin Injections No Help for Postoperative AF: NOVA

News Conference News AHA 2022

Botulinum Toxin Injections No Help for Postoperative AF: NOVA

Yael L. Maxwell

November 07, 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

November 07, 2022

First-line Ablation Reduces AF Progression, Boosts Quality of Life

News Conference News AHA 2022

First-line Ablation Reduces AF Progression, Boosts Quality of Life

November 07, 2022

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

News Conference News AHA 2022

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

November 06, 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

November 06, 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

News Conference News AHA 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

November 06, 2022

RAPCO: Radial Artery Beats of Both RITA and Vein Grafting at 15 Years

News Conference News AHA 2022

RAPCO: Radial Artery Beats Both RITA and Vein Grafting at 15 Years

Yael L. Maxwell

November 06, 2022

CRISPR/Cas-9 Gene Editing Shows Promise in Transthyretin Amyloidosis

News Conference News AHA 2022

CRISPR/Cas-9 Gene Editing Shows Promise in Transthyretin Amyloidosis

Yael L. Maxwell

November 05, 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

News Conference News AHA 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

November 05, 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF

News Conference News AHA 2022

TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF

November 05, 2022

CAST-HF: Could Myocardial Shockwave During CABG Yield Cardiac Regeneration?

News Conference News EACTS 2022

CAST-HF: Could Myocardial Shockwave During CABG Yield Cardiac Regeneration?

October 12, 2022

Adjunctive Radial Artery Grafts No Better Than SVGs in Multivessel CABG

News Conference News EACTS 2022

Adjunctive Radial Artery Grafts No Better Than SVGs in Multivessel CABG

Michael O'Riordan

October 12, 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

News Conference News HFSA 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

October 07, 2022

GDMT With ARNI Lessens MR, Perhaps Obviating Need for Interventions

News Conference News HFSA 2022

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Michael O'Riordan

October 04, 2022

Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER

News Conference News HFSA 2022

Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER

October 04, 2022

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

News Conference News TCT 2022

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

September 23, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.